Overview


According to FutureWise analysis the market for angiosarcoma treatment is expected to register a CAGR of 5.30% from 2023-2031.

Angiosarcoma is a rare and highly aggressive malignancy associated with endothelial cells in blood or lymphatic vessels. This form of cancer can be seen throughout the body, with common sites including cutaneous lesions, especially on the head and neck, and within soft tissues, visceral organs, bone, and the retroperitoneum. Due to its non-specific symptoms, often leading to confusion with other malignant neoplasms, its diagnosing is challenging. Although imaging techniques like ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are helpful, histological examination with immunohistochemical confirmation remains essential. Angiosarcoma is characterized by its definite features like infiltrative nature, high rates of local recurrence, and metastasis. Advanced or metastatic disease is observed in a significant portion of cases at presentation, resulting in varying overall survival rates. The cornerstone of treatment remains radical surgery, though achieving negative surgical margins can be challenging. Adjuvant radiotherapy following surgery has shown promise in improving local control. Radiotherapy has evolved as an essential treatment modality, particularly for inoperable cases or those with a high risk of recurrence. Definitive radiotherapy is being explored for unresectable tumors. Chemotherapy becomes vital in treating angiosarcoma with agents like anthracyclines (e.g., doxorubicin) and taxanes (e.g., paclitaxel) commonly used. Anthracycline-based regimens have demonstrated effectiveness, and liposome-encapsulated doxorubicin is considered for patients who may not tolerate standard doxorubicin.

Overall, due to the rarity of angiosarcoma and the complexity of its treatment, a multidisciplinary approach involving surgery, radiotherapy, chemotherapy, and targeted therapies is often employed. Further research and clinical trials are needed to refine treatment strategies and improve outcomes for patients with angiosarcoma.

FutureWise Market Research has published a report that provides an insightful analysis of Angiosarcoma Treatment Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Angiosarcoma Treatment Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer Inc.
  • Amgen Inc.
  • Genetech, Inc.
  • Sanofi S.A.
  • Bayer AG
  • Johnson and Johnson

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Angiosarcoma Treatment Market:

  • Novartis disclosed that the U.S. Food and Drug Administration (FDA) had granted official approval for its Durham, N.C. site, a cutting-edge gene therapy manufacturing facility capable of producing, testing, and releasing commercial Zolgensma. Furthermore, the facility is authorized to manufacture gene therapy products for ongoing and forthcoming clinical trials, in April 2022.

The rising prevalence of angiosarcoma cases significantly drives this angiosarcoma treatment market. Ongoing technological advancements in oncology and sarcoma treatment, more research and development for sarcomas and cancer treatment and their drugs, and the development of new effective therapies are enhancing the market growth. Funds are being raised by governments, private organizations, and pharmaceutical companies investing heavily, which supports the development of new therapeutics and accelerates market growth. With an increased geriatric population, there are high-risk chances of angiosarcoma affecting aged individuals, driving the demand for the market. Well-developed health infrastructure and the expansion of healthcare industries are propelling market growth.

However, there are several restraints affecting the market growth. Angiosarcoma is a rare disease with no specific treatment and studies for the underlying mechanisms, proving it as a challenge for developing new therapies. Also, more FDA-approved treatments for angiosarcoma must be available, which again hampers the market. The high cost of the treatment, especially the chemotherapy and immunotherapy associated with these, may limit access for some of the patients, particularly those with adequate insurance coverage, which is depleting the market growth.

By Treatment Type

  • Chemotherapy
  • Immunotherapy

By Location of Instigation

  • Hemangiosarcoma
  • Lymphangiosarcoma

By End User

  • Hospitals
  • Cancer Treatment Centres
  • Ambulatory Surgical Centres

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America holds the largest market share due to the well-established health infrastructure, early adoption of technological advancements, high healthcare expenditure, angiosarcoma cases, and lymphedema and syncope, which are increasing in this region. Whereas Asia-Pacific is a rapidly growing market due to the increasing rate of geriatric populations and high prevalence of cancer in older adults, expanded access to healthcare services and improvised healthcare infrastructure are driving the market growth in this region. In addition, government initiatives are playing a significant role in raising funds and promoting advanced healthcare technologies.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Angiosarcoma Treatment Market By Treatment Type, By Location of Instigation, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Angiosarcoma Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Angiosarcoma Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Angiosarcoma Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Angiosarcoma Treatment Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chemotherapy
        2. Immunotherapy

  • 8.   Angiosarcoma Treatment Market, By Location of Instigation Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hemangiosarcoma
        2. Lymphangiosarcoma

  • 9.   Angiosarcoma Treatment Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Cancer Treatment Centres
        3. Ambulatory Surgical Centres

  • 10.   North America Angiosarcoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Angiosarcoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Angiosarcoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Angiosarcoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Amgen Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Genetech, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sanofi S.A.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bayer AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson and Johnson
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients